There’s nothing quite like getting a new paper out as a scientist running a research lab so this week we can celebrate our new pediatric brain tumor study. I’ll start the weekly reads with that paper. Of course, getting new grants is amazing too but there’s more of a feel of completion after a paper […]
Weekly reads: our new brain tumor paper, levitation, dear doctor, Japan, more Read More »
A new Nature paper argues that young CSF fights brain aging. Young CSF vs. young blood CSF is the cerebrospinal fluid that surrounds the brain, including those of young mice. The claim is that when young CSF is injected into the brain/CNS cavity of old mice, it makes the aged brains seem younger. And function
Nature paper claims young CSF fights brain aging in mice Read More »
This has been one of those weeks where I spent some time thinking about taking risks in science. How much risk one should take? Risks can come in many forms. It could be at the core level at the bench doing specific experiments and not others. There’s risk in clinical trials, and even in advocacy. Sometimes
Weekly science reads: Macchiarini trial, somites, CRISPR babies Read More »
We often don’t think of them that way but reproductive cells like sperm and egg are also relatives of stem cells, and it turns out that there are stem cells that make the reproductive cells too like sperm stem cells. Sperm and germ cell stem cells DNMT3A-dependent DNA methylation is required for spermatogonial stem cells
Recommend reads: CRISPR baby guy free, DNMT3, sperm, Editas, hearing loss, reprogramming Read More »
At the beginning of the year I wrote about a new kind of biotech called Altos Labs. It’s very different in some ways from other institutions. I find it an intriguing research entity. Where do things stand now with Altos Labs a few months later? More information, new ideas, and questions have popped up in the
Altos Labs: mission, leadership, jobs, & CIRM Read More »
David Weinberg over at Science-Based Medicine has his part two of a deep dive into the so-called SCOTS trial, which is a non-traditional pay-for-play study. I highly recommend it. SCOTS trial under the magnifying glass In this piece, Weinberg provides interesting background on the two people running SCOTS. I’ve had many concerns about the SCOTS
Recommended reads: engineered niche, ALS, SCOTS trial, human genome “done” Read More »
Many firms that generally fall into the category of unproven stem cell or cell therapy clinics have a way of reinventing themselves and I’ve seen this with one formerly named the Lung Institute that is now called Centers for Respiratory Health. First the Lung Institute became the Lung Health Institute. Now that firm has become
Centers for Respiratory Health is new incarnation of clinic Lung Health Institute Read More »
The FDA has been busy with the COVID pandemic but it has many other things on its plate as well including cell therapies. Today I’m sharing some recent agency news and brief perspectives on it. FDA focus on clinic-related umbilical cord cell drug makers The agency warned an Idaho company that produces and sells umbilical
FDA news: warning letter pattern, cancer moonshot, CAR-T & gene-editing guidance Read More »
I’m fascinated by the idea of making food from cells grown in a lab and especially the newest idea of lab-grown chocolate. While lab-grown meat has gotten the most attention, (see my recent post on test-tube meat: Not Old MacDonald’s Farm: is the future lab-grown meat?) I’d say that the coolest application of making food from
Biotech California Cultured aims to sell lab-grown chocolate Read More »
Before starting the umbilical cord cell supplier and marketing firm Liveyon, John Kosolcharoen was involved in some alleged health care fraud. The feds brought a case against him related to prescription drugs. Older case coming to a head As Liveyon was having its misadventures in the stem cell clinic sphere, the status of that past
Feds want $3M, prison for Liveyon founder in old fraud case Read More »